OrbiMed and Oceanpipe Lead USD130m Series B for China’s Yisheng Biopharma
Source(s): DealStreetAsia
OrbiMed and Oceanpipe Capital led a USD130m Series B for China-based biopharmaceutical company Yisheng Biopharma. Read more
Source(s): DealStreetAsia
OrbiMed and Oceanpipe Capital led a USD130m Series B for China-based biopharmaceutical company Yisheng Biopharma. Read more